europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

EuropaBio sat down with new Member Bon Vivant, to learn more about the future of alternative dairy proteins

21/09/2022
INTERVIEW
SMM

About Stéphane Mac Millan
An entrepreneur at heart, Stéphane has participated in the launch and scale up of two start-ups in Europe. He also worked in strategic consulting before the launch of Bon Vivant.

Interview with... Stéphane Mac Millan, Co-Founder & CEO at Bon Vivant

1) What inspired the foundation of Bon Vivant?
When I turned 30 years old, I decided that my next entrepreneurial endeavour would have to meet two criteria i) help tackle at least one of the major issues our generation is facing ii) have an impact at a large scale. When I discovered that if we applied precision fermentation to dairy proteins it would have a positive impact on the environment, animal welfare and human health and all of these at an industrial level, I simply got obsessed about creating a European champion.

2) What potential do you see in demand for alternative dairy products?
Dairy products are simply one of the best sources of proteins. Besides, the diversity of dairy products (e.g., cheese, yogurts, ice cream, chantilly, etc.) makes it a major part of most human being alimentation. But the problem is that the way we are producing the milk necessary for our dairy products is simply not sustainable and it will only become worst with the growing population. Therefore, we absolutely need to invent new complementary way of production.

3) What are your plans for growth?
We are building our portfolio of animal-free milk proteins and ready-mix. The objective is to be the most innovative dairy ingredients provider to serve the demand of dairy manufacturers and help them recreate their iconic products and also invent new ones.

4) How do you see Bon Vivant being able to transform the dairy industry's impact on climate change and animal welfare?
We are working hand in hand with dairy manufacturers to understand their needs and create for them the solutions they want. We are lucky to partner with some of the major players in the world. So, if only we could answer 10% of their needs in animal-free milk proteins, then our impact would be colossal, and our mission fulfilled.

Bon Vivant – Interview with post

Interview with Bon Vivant


Download
2022_09_G_O_Interview-with-Bon-VivantDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies